cordite-api.uni-muenster.de Open in urlscan Pro
128.176.232.157  Public Scan

Form analysis
0 forms found in the DOM

Text Content

CORONA DRUG INTERACTIONS DATABASE


Interactions Targets Drugs Publications Clinical trials About


Show 2050100200All entries
Search:

TargetTarget affiliationDrugTypeResult TargetTarget affiliationDrugTypeResult 3a
Ion channelSARS-CoV-2PentamidineIn vitropositive3a Ion
channelSARS-CoV-2Fludarabine In vitropositive3a Ion
channelSARS-CoV-2FloxuridineIn vitropositive3a Ion
channelSARS-CoV-2CapreomycinIn vitropositive3a Ion channelSARS-CoV-2PlerixaforIn
vitropositive3a Ion channelSARS-CoV-2SpectinomycinIn vitropositive3a Ion
channelSARS-CoV-2KasugamycinIn vitropositive3a Ion channelSARS-CoV-2FlumatinibIn
vitropositive3a Ion channelSARS-CoV-2LitronesibComputationalpositive3a Ion
channelSARS-CoV-2DarapladibIn vitropositive3C-like
proteaseSARS-CoV-2LedipasvirComputationalpositive3C-like
proteaseSARS-CoV-2VelpatasvirComputationalpositive3C-like
proteaseSARS-CoV-2DiosminComputationalpositive3C-like
proteaseSARS-CoV-2HesperidinComputationalpositive3C-like
proteaseSARS-CoV-2TeniposideComputationalpositive3C-like
proteaseSARS-CoV-2EtoposideComputationalpositive3C-like
proteaseSARS-CoV-2VenetoclaxComputationalpositive3C-like
proteaseSARS-CoV-2MercaptopurineComputationalpositive3C-like
proteaseSARS-CoV-2SirolimusComputationalpositive3C-like
proteaseSARS-CoV-2CarvedilolComputationalpositive3C-like
proteaseSARS-CoV-2EmodinComputationalpositive3C-like
proteaseSARS-CoV-2LopinavirClinical trialnegative3C-like
proteaseSARS-CoV-2LopinavirComputationalpositive3C-like
proteaseSARS-CoV-2RitonavirComputationalnegative3C-like
proteaseSARS-CoV-2RitonavirComputationalpositive3C-like
proteaseSARS-CoV-2RibavirinComputationalpositive3C-like
proteaseSARS-CoV-2ChloroquineComputationalpositive3C-like
proteaseSARS-CoV-2ChloroquineComputationalnegative3C-like
proteaseSARS-CoV-2CiclesonideComputationalpositive3C-like
proteaseSARS-CoV-2Favipiravir Computationalpositive3C-like
proteaseSARS-CoV-2Favipiravir Computationalnegative3C-like
proteaseSARS-CoV-2RemdesivirComputationalpositive3C-like
proteaseSARS-CoV-2DarunavirIn vitropositive3C-like
proteaseSARS-CoV-2DarunavirComputationalpositive3C-like
proteaseSARS-CoV-2DarunavirComputationalnegative3C-like
proteaseSARS-CoV-2IndinavirComputationalpositive3C-like
proteaseSARS-CoV-2IndinavirComputationalnegative3C-like
proteaseSARS-CoV-2SaquinavirComputationalpositive3C-like
proteaseSARS-CoV-2AtazanavirComputationalpositive3C-like
proteaseSARS-CoV-2TipranavirComputationalpositive3C-like
proteaseSARS-CoV-2FosamprenavirComputationalpositive3C-like
proteaseSARS-CoV-2EnzaplatovirComputationalpositive3C-like
proteaseSARS-CoV-2AbacavirComputationalpositive3C-like
proteaseSARS-CoV-2CinanserinComputationalpositive3C-like
proteaseSARS-CoV-2TeicoplaninIn vitropositive3C-like
proteaseSARS-CoV-2CepharanthineComputationalpositive3C-like
proteaseSARS-CoV-2CepharanthineIn vitronegative3C-like
proteaseSARS-CoV-2Mefloquine hydrochlorideComputationalpositive3C-like
proteaseSARS-CoV-2TelcagepantComputationalpositive3C-like
proteaseSARS-CoV-2VidupiprantComputationalpositive

Showing 1 to 50 of 1,810 entries
 * Previous
 * 1
 * 2
 * 3
 * 4
 * 5
 * …
 * 37
 * Next



Show 102550100 entries
Search:

NameSynonymsGenesOrigin NameSynonymsGenesOrigin 3a Ion channelSARS-CoV-23C-like
protease3CLpro, Mpro, SARS coronavirus main peptidase, 3CLpro-SARS-CoV-2rep,
ORF1a-1bSARS-CoV-2ADP ribose phosphatase of NSP3SARS-CoV-2Angiotensin Converting
EnzymeACE1,ACEAngiotensin-converting enzyme 2ACE-related carboxypeptidase,
ACE2ACE2Homo sapiensAngiotensin-converting enzyme 2-Spike glycoprotein
interfaceBasiginCD_antigen: CD147, 5F7, Collagenase stimulatory factor,
Leukocyte activation antigen M6, Extracellular matrix metalloproteinase inducer,
Tumor cell-derived collagenase stimulatory factorBsgHomo sapiensCathepsin BAPP
secretase, APPS, Cathepsin B1CTSB, CPSBHomo sapiensCathepsin LCTSLHomo
sapiensDihydroorotate dehydrogenase (quinone), mitochondrialDHODH, DHOdehase,
Dihydroorotate oxidaseDHODHHomo sapiensEndopeptidase C30Peptidase C30rep,
ORF1a-1bSARS-CoV-2Envelop proteinSARS-CoV-2ExoribonucleaseExoN, Non-structural
protein14, Nonstructural protein14, nsp14, 5‘-to-3‘ exonucleaserep,
ORF1a-1bSARS-CoV-2FurinFURINHomo sapiensGCSF-Receptor Signaling ComplexCSF3 Homo
sapiensheat shock protein A4Heat Shock Protein Family A (Hsp70) Member
4HSPA4Homo sapiensHelicaseHelicase, nsp13, Hel, p66, p66-HEL, Non-structural
protein 13rep, ORF1a-1bSARS-CoV-2Interleukin 1 betaIL-1β, leukocytic pyrogen,
leukocytic endogenous mediator, mononuclear cell factor, lymphocyte activating
factorIL1BHomo sapiensInterleukin-6 receptorIL-6RIL6Homo
sapiensN-acylethanolamine-hydrolyzing acid amidaseNAAAHomo
sapiensNeuropilin-1NRP1,Homo sapiensnsp1non-structure protein
1SARS-CoV-2nsp16/nsp10 complexrep, ORF1a-1bSARS-CoV-2nsp2Non-structural protein
2SARS-CoV-2nsp4Non-structural protein 4nsp9replicaseSARS-CoV-2NTD-N-proteinN
terminal domain of Nucleocapsid proteinSARS-CoV-2Papain-like proteinases
1/2Non-structural protein 3, papain like viral protease, nsp3, PL1-PRO/PL2-PRO,
PLP1/PLP2, p195, Plprorep, ORF1a-1bSARS-CoV-2Putative 2'-O-methyl
transferase2’-O-Ribose methyltransferase, Non-structural protein 16,
Nonstructural protein 16, nsp16rep, ORF1a-1bSARS-CoV-2RNA dependent RNA
polymeraseRDR, viral RNA polymerase, RdRp, nsp12rep, ORF1a-1b, RdRpSARS-CoV-2S2
proteinSARS-CoV-2 S protein S2 subunitSARS-CoV-2Sigma-1 receptorSIGMAR1, ALS16,
OPRS1, SIG-1R, SR-BP, SR-BP1, SRBP, hSigmaR1, sigma1R, DSMA2, sigma non-opioid
intracellular receptor 1Homo sapiensSpike glycoproteinSpike protein, S
glycoprotein, S-Protein, S1, S2, S3, Peplomer protein, E2S,
ORF2SARS-CoV-2Transmembrane serine 2TMPRSS2, Serine protease 10TMPRSS2,
PRSS10Homo sapiensTransmembrane serine 2-Cathepsin B
interfaceUnspecificSARS-CoV-2Uridylate-specific endoribonucleaseNSP15,
Non-structural protein 15, Nonstructural protein 15, NendoU, endoRNAserep,
ORF1a-1bSARS-CoV-2

Showing 1 to 37 of 37 entries
 * Previous
 * 1
 * Next



Show 2050100200All entries
Search:

NameSynonymsPubChemDrugBankRCSB PDBATC NameSynonymsPubChemDrugBankRCSB PDBATC
Adenosine phosphate5'-Adenosine monophosphate, 5'-Adenylic acid, 5'-AMP,
Adenylate, Adenosine-5'P, AMP, Adenylate6083DB00131
6-CARBAMIMIDOYL-4-(3-HYDROXY-2-METHYL-BENZOYLAMINO)-NAPHTHALENE-2-CARBOXYLIC
ACID METHYL ESTERDB07074DB07074 Abiraterone acetate9821849DBSALT001173
ABP-70071481187DB15411 AT-751911338033DB08142 Carindacillin DB09319
Cordycepin6303 DB12156
D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamideDB07005DB07005
DicyclomineDicycloverine3042DB00804 DinoprostDB12789 Indium In-111
oxyquinolineDB09473 Interferon alfa-2bIFN-alpha2b, Interferon alfa-2b,
Interferon alpha-2B, Interferon α-2b, Intron (Interferon α2b), Intron A, Intron
A (Interferon α2b), r-INF-alpha, rIFN-alpha-2b DB00105
N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDEDB07779DB07779(-)-Epigallocatechin
gallate65064(2R,3R,4R,5R)-2-(hydroxymethyl)-5-[(5-phenyl-4-pyridin-3-yltriazol-1-yl)methyl]pyrrolidine-3,4-diol11210821(2S)-1-(1H-indol-3-yl)-3-{[5-(3-methyl-
1H-indazol-5-yl)pyridin-3-yl]oxy} propan-2-amineDB08073(2S)-Eriodictyol
7-O-(6″-O-galloyl)-beta-D-glucopyranoside10930068(2S)-N-[(1S,3S,4S)-1-Benzyl-4-[[2-(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-pentyl]-2-(2,3-dioxopiperazin-1-yl)-3-methyl-butanamideCHEMBL91798
,
SCHEMBL20589713010249(2S)-N-[(1S,3S,4S)-4-[[2-(4-Amino-2,6-dimethyl-phenoxy)acetyl]amino]-1-benzyl-3-hydroxy-5-phenyl-pentyl]-3-methyl-2-(2-oxohexahydropyrimidin-1-yl)butanamide(2S)-N-[(1S,3S,4S)-4-[[2-(4-amino-2,6-dimethyl-phenoxy)acetyl]amino]-1-benzyl-3-hydroxy-5-phenyl-pentyl]-3-methyl-2-(2-oxohexahydropyrimidin-1-yl)butanamide
, 1(2H)-Pyrimidineacetamide,
N-[(1S,3S,4S)-4-[[2-(4-amino-2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-.alpha.-(1-methylethyl)-2-oxo-,
(a1S)-492005(2S,3S,4R,5R)-2-(4-Amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methylpyrrolidine-3,4-diol11687749(2S,3S,4S,5R)-6-[5-[(2S,3S,4S,5R)-6-[2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxane-2-carbonyl]oxy-7-hydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic
acid88507127(8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic
acid46937061DB072091,10-PhenanthrolineDB023651-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamideDB0689610'-Hydroxyusambarensine4456637710-Hydroxycamptothecin(S)-10-Hydroxycamptothecin,
Hydroxycamptothecin972262'-Deoxy-2'-fluorocytidine2'-Fluoro-2'-deoxycytidine,
1015072'-deoxy-N-(naphthalen-1-ylmethyl)guanosine 5'-(dihydrogen
phosphate)DB082372-(2f-Benzothiazolyl)-5-Styryl-3-(4f-Phthalhydrazidyl)Tetrazolium
ChlorideDB018976105620DB018972-(4-Amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidine-1-carboxylic
acid1236242082-(N-Morpholino)-ethanesulfonic
acid44782492-[(2,4-dichloro-5-methylphenyl)
sulfonyl]-1,3-dinitro-5-(trifluoromethyl)
benzeneDB076202-[3-({Methyl[1-(2-Naphthoyl)Piperidin-4-Yl]Amino}Carbonyl)-2-Naphthyl]-1-(1-Naphthyl)-2-Oxoethylphosphonic
AcidDB040162-[7-but-2-ynyl-1-(2-ethoxyethyl)-2,6-dioxo-8-piperazin-1-ylpurin-3-yl]acetic
acid
220294413-(1H-benzimidazol-2-yl)-1H-indazoleDB079593-(1h-Indol-3-Yl)-2-[4-(4-Phenyl-Piperidin-1-Yl)-Benzenesulfonylamino]-Propionic
AcidDB024493-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDEDB069253-(5-amino-7-hydroxy-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(3,5-dichlorobenzyl)-benzamideDB035713-(5-Amino-7-oxo-3,7-dihydro-2H-[1,2,3]triazolo[4,5-d]pyrimidin-2-yl)-N-(2-{[2-(hydroxymethyl)phenyl]sulfanyl}benzyl)benzamideDB032314-(dimehylamina)
benzoic
acid2434-[[2-[[4-chloro-3-(trifluoromethyl)phenyl]amino]-3H-benzimidazol-5-yl]oxy]-N-methyl-pyridine-2-carboxamideDB069384-{2,4-Bis[(3-Nitrobenzoyl)Amino]Phenoxy}Phthalic
AcidDB0306747D11mAb 47D114SC-202Domatinostat
(tosylate)DB13101DB131015,7,3′,4′-Tetrahydroxy-2'-(3,3-dimethylallyl)
isoflavone116100525-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indoleDB068285-Fluorouracil5-FU,
fluorouracil3385DB00544L01BC026,7,12,13-tetrahydro-5H-indolo[2,3-a]
pyrrolo[3,4-c]carbazol-5-oneDB080366-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-NaphthamideDB030826-amino-2-[(1-naphthylmethyl)amino]-
3,7-dihydro-8H-imidazo[4,5-g] quinazolin-8-oneDB08512

Showing 1 to 50 of 1,172 entries
 * Previous
 * 1
 * 2
 * 3
 * 4
 * 5
 * …
 * 24
 * Next



Show 2050100200All entries
Search:

TitleAuthorsDOISourceArticle typeDate TitleAuthorsDOISourceArticle typeDate An
overview of current drugs and prophylactic vaccines for coronavirus disease 2019
(COVID-19).Alagheband Bahrami, Armina Azargoonjahromi, Ali Sadraei, Samin
Aarabi, Aryan Payandeh, Zahra Rajabibazl,
Masoumeh10.1186/s11658-022-00339-3PMCReview2022-05-12Multifaceted role of
natural sources for COVID-19 pandemic as marine drugs.Rahman, MominurIslam,
RezaulShohag, SheikhHossain, EmonShah, Muddasershuvo, Shakil khanKhan,
HosnearaChowdhury, Arifur RahmanBulbul, Israt JahanHossain, SarowarSultana,
SharifaAhmed, MuniruddinAkhtar, Muhammad FurqanSaleem, AmmaraRahman,
Habibur10.1007/s11356-022-20328-5PMCReview2022-05-03Recent Advances in Passive
Immunotherapies for COVID-19: The Evidence-Based Approaches and Clinical
Trials.Farhangnia, PooyaDehrouyeh, ShivaSafdarian, Amir RezaFarahani, Soheila
VasheghaniGorgani, MelikaRezaei, NimaAkbarpour, MahzadDelbandi,
Ali-Akbar10.1016/j.intimp.2022.108786PMCReview2022-04-20Can anti-parasitic drugs
help control COVID-19?Panahi, YasinDadkhah, MasoomehTalei, SahandGharari,
ZahraAsghariazar, VahidAbdolmaleki, ArashMatin, SomayehMolaei,
Soheila10.2217/fvl-2021-0160PMCReview2022-02-27COVID-19 at a Glance: An
Up-to-Date Overview on Variants, Drug Design and Therapies.Iacopetta,
DomenicoCeramella, JessicaCatalano, AlessiaSaturnino, CarmelaPellegrino,
MicheleMariconda, AnnaluisaLongo, PasqualeSinicropi, Maria StefaniaAquaro,
Stefano10.3390/v14030573PMCReview2022-03-09A Systematic Review of the Global
Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir
Approval.Ashour, Nada AAbo Elmaaty, AymanSarhan, Amany AElkaeed, Eslam BMoussa,
Ahmed MErfan, Ibrahim AliAl-Karmalawy, Ahmed
A10.2147/DDDT.S354841PMCReview2022-03-14An umbrella review and meta-analysis of
the use of renin-angiotensin system drugs and COVID-19 outcomes: what do we know
so far? A. Kurdi, N. Weir, T.
Mueller,10.1101/2022.03.20.22272664MedRxivReview2022-03-20Mechanism of Action of
Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.Zhao,
LeiLi, SongZhong, Wu10.3389/fphar.2022.840639PMCReview2022-02-24Drug repurposing
against SARS-CoV-2 using computational approaches.Kumar, SumitKovalenko,
SvitlanaBhardwaj, ShakshiSethi, AaftaabYu. Gorobets, NikolayDesenko, Sergey
M.PoonamRathi, Brijesh10.1016/j.drudis.2022.02.004PMCReview2022-02-09Advances in
the development of therapeutic strategies against COVID-19 and perspectives in
the drug design for emerging SARS-CoV-2 variants.Yin, JialingLi, ChengchengYe,
ChunhongRuan, ZhihuiLiang, YicongLi, YongkuiWu, JianguoLuo,
Zhen10.1016/j.csbj.2022.01.026PMCReview2022-01-30Structure genomics of
SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19.Wu,
Can-rongYin, Wan-chaoJiang, YiXu, H.
Eric10.1038/s41401-021-00851-wPMCReview2022-01-19Interferon Control of Human
Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications
for Antiviral Drug and Vaccine Development.Zhao, XuesenChen, DanyingLi,
XinglinGriffith, LaurenChang, JinhongAn, PingGuo,
Ju-Tao10.1016/j.jmb.2021.167438PMCReview2022-01-02A Review on Repurposed Drugs
and Vaccine Trials for Combating SARS CoV-2.Nikita Khanna, Sandip V Pawar, Anil
Kumar, 10.2174/2589977513666210315094752PubMedReviewAn update on drugs with
therapeutic potential for SARS-CoV-2 (COVID-19) treatment.Drożdżal,
SylwesterRosik, JakubLechowicz, KacperMachaj, FilipSzostak, BartoszPrzybyciński,
JarosławLorzadeh, ShahrokhKotfis, KatarzynaGhavami, SaeidŁos, Marek
J.10.1016/j.drup.2021.100794PMCReview2021-12-08Drug-based therapeutic strategies
for COVID-19-infected patients and their challenges.Zarkesh,
KhaterehEntezar-Almahdi, ElahehGhasemiyeh, ParisaAkbarian, MohsenBahmani,
MarziehRoudaki, ShahrzadFazlinejad, RahilMohammadi-Samani, SolimanFirouzabadi,
NegarHosseini, MajidFarjadian,
Fatemeh10.2217/fmb-2021-0116PMCReview2021-10-11Coronavirus Disease (COVID-19)
Control between Drug Repurposing and Vaccination: A Comprehensive
Overview.Al-Karmalawy, Ahmed A.Soltane, RayaAbo Elmaaty, AymanTantawy, Mohamed
A.Antar, Samar A.Yahya, GalalChrouda, AmaniPashameah, Rami AdelMustafa,
MuhamadAbu Mraheil, MobarakMostafa,
Ahmed10.3390/vaccines9111317PMCReview2021-11-11Structures and functions of
coronavirus replication–transcription complexes and their relevance for
SARS-CoV-2 drug design.Malone, BrandonUrakova, NadyaSnijder, Eric J.Campbell,
Elizabeth A.10.1038/s41580-021-00432-zPMCReview2021-11-24Molnupiravir in
COVID-19: A systematic review of literaturefAwadhesh Kumar Singh , Akriti Singh
, Ritu Singh , Anoop Misra10.1016/j.dsx.2021.102329PubMedReview2021-11-14Drug
repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.Aherfi, SarahPradines,
BrunoDevaux, ChristianHonore, StéphaneColson, PhilippeScola, Bernard LaRaoult,
Didier10.2217/fmb-2021-0019PMCReview2021-10-07Clinical features and mechanistic
insights into drug repurposing for combating COVID-19.Asrani, PurvaTiwari,
KeshavEapen, Mathew SujiMcAlinden, Kielan DarcyHaug, GregJohansen, Matt
DHansbro, Philip MFlanagan, Katie LHassan, Md. ImtaiyazSohal, Sukhwinder
Singh10.1016/j.biocel.2021.106114PMCReview2021-11-04Current status of
structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2
proteins.Hijikata, AtsushiShionyu, ClaraNakae, SetsuShionyu, MasafumiOta,
MotonoriKanaya, ShigehikoShirai,
Tsuyoshi10.2142/biophysico.bppb-v18.025PMCReview2021-10-04An updated review on
potential therapeutic drug candidates, vaccines and an insight on patents filed
for COVID-19.Rao, G.S.N. KoteswaraGowthami, BuduruNaveen, N.
RaghavendraSamudrala, Pavan
Kumar10.1016/j.crphar.2021.100063PMCReview2021-10-07Clinical drug therapies and
biologicals currently used or in clinical trial to treat COVID-19.Malek, Rory
J.Bill, Colin A.Vines, Charlotte
M.10.1016/j.biopha.2021.112276PMCReview2021-10-01Deleterious drugs in COVID-19:
a rapid systematic review and meta-analysisMichael Holder, Catherine Heeney,
Stephen Malden, Uditha Perera, Aziz
Sheikh10.1101/2021.09.17.21262724MedRxivReview2021-09-20Use of the rheumatic
drug tocilizumab for treatment of SARS-CoV-2 patients.Grygiel-Górniak,
BognaShaikh, OsamaKumar, Nikita NiranjanHsu, Shao HengSamborski,
Włodzimierz10.5114/reum.2021.108554PMCReview2021-08-19Recent progress in the
development of potential drugs against SARS-CoV-2.Chen, JianminAli, FayazKhan,
ImranZhu, Yi Zhun10.1016/j.crphar.2021.100057PMCReview2021-09-13Drug repurposing
against coronavirus disease 2019 (COVID-19): A review.Luo, LianxiangQiu,
QinHuang, FangfangLiu, KaifengLan, YongqiLi, XiaolingHuang, YugeCui, LiaoLuo,
Hui10.1016/j.jpha.2021.09.001PMCReview2021-09-03Bias as a source of
inconsistency in ivermectin trials for COVID-19: A systematic reviewAriel
Izcovich, Sasha Peiris, Martín Ragusa, Fernando Tortosa, Gabriel Rada, Sylvain
Aldighieri, Ludovic Reveiz10.1101/2021.08.19.21262304MedRxivReview2021-08-20Oral
disease-modifying antirheumatic drugs and immunosuppressants with antiviral
potential, including SARS-CoV-2 infection: a review.Tsai, Y. C.Tsai, T.
F.10.1177/1759720X20947296PMCReview2020-09-02Potential Drugs and Remedies for
the Treatment of COVID-19: a Critical Review.Barati, FatemehPouresmaieli,
MahdiEkrami, ElenaAsghari, SaharZiarani, Farzad RamezaniMamoudifard,
Matin10.1186/s12575-020-00129-1PMCReview2020-07-22An Updated Review of
Computer-Aided Drug Design and Its Application to COVID-19.Gurung, Arun
BahadurAli, Mohammad AjmalLee, JoongkuFarah, Mohammad AbulAl-Anazi, Khalid
Mashay10.1155/2021/8853056PMCReview2021-06-23Roles of existing drug and drug
targets for COVID-19 management.Ayele, Akeberegn GoremsEnyew, Engidaw
FentahunKifle, Zemene
Demelash10.1016/j.metop.2021.100103PMCReview2021-06-28Therapeutic Effectiveness
and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing
in 2021.Alam, SafaetKamal, Taslima BinteSarker, Md. Moklesur RahmanZhou,
Jin-RongRahman, S. M. AbdurMohamed, Isa
Naina10.3389/fphar.2021.659577PMCReview2021-06-13COVID-19: Vaccine Delivery
System, Drug Repurposing and Application of Molecular Modeling Approach.Abd El
Hadi, Soha RZien El-Deen, Esmat EBahaa, Mostafa MSadakah, Abdelfattah AYassin,
Heba A10.2147/DDDT.S320320PMCReview2021-07-29Role of Inflammatory Cytokines in
COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions,
Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm.Rabaan, Ali
A.Al-Ahmed, Shamsah H.Muhammad, JavedKhan, AmjadSule, Anupam ATirupathi,
RaghavendraMutair, Abbas AlAlhumaid, SaadAl-Omari, AwadDhawan, ManishTiwari,
RuchiSharun, KhanMohapatra, Ranjan K.Mitra, SaikatBilal, MuhammadAlyami, Salem
A.Emran, Talha BinMoni, Mohammad AliDhama,
Kuldeep10.3390/vaccines9050436PMCReview2021-04-28Drug repurposing for COVID-19:
Approaches, challenges and promising candidates.Ng, Yan LingSalim, Cyrill
KafiChu, Justin Jang
Hann10.1016/j.pharmthera.2021.107930PMCReview2021-06-22Repurposing Drugs,
Ongoing Vaccine, and New Therapeutic Development Initiatives Against
COVID-19.Saha, Rudra P.Sharma, Ashish RanjanSingh, Manoj K.Samanta,
SaikatBhakta, SwarnavMandal, SnehasishBhattacharya, ManojitLee,
Sang-SooChakraborty,
Chiranjib10.3389/fphar.2020.01258PMCReview2020-08-18Systematic review on role of
structure based drug design (SBDD) in the identification of anti-viral leads
against SARS-Cov-2.Bajad, Nilesh GajananRayala, SwethaGutti, GopichandSharma,
AnjaliSingh, MeenakshiKumar, AshokSingh, Sushil
Kumar10.1016/j.crphar.2021.100026PMCReview2021-05-13Antivirals Against
Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?Santos, Igor de
AndradeGrosche, Victória RiquenaBergamini, Fernando Rodrigues
GoulartSabino-Silva, RobinsonJardim, Ana Carolina
Gomes10.3389/fmicb.2020.01818PMCReview2020-08-12SARS-CoV-2 spike protein and RNA
dependent RNA polymerase as targets for drug and vaccine development: A
review.Muhammed, YusufYusuf Nadabo, AbduljalalPius, MkpoutoSani, BashiruUsman,
JafarAnka Garba, NasirMohammed Sani, JaafaruOpeyemi Olayanju, BasitZeal Bala,
SundayGarba Abdullahi, MusaSambo,
Misbahu10.1016/j.bsheal.2021.07.003PMCReview2021-07-20Candidate drugs against
SARS-CoV-2 and COVID-19.Dwight L McKee, Ariane Sternberg, Ulrike Stange, Stefan
Laufer, Cord Naujokat, 10.1016/j.phrs.2020.104859PubMedReview2020-04-28Current
approaches for target-specific drug discovery using natural compounds against
SARS-CoV-2 infection.Prashant Khare, Utkarsha Sahu, Satish Chandra Pandey,
Mukesh Samant, 10.1016/j.virusres.2020.198169PubMedReview2020-09-23A Review on
the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really
Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Variants?Rashed Noor, 10.1007/s40588-021-00172-wPubMedReview2021-07-02The
SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological
Functions, and a Potential Target for Drug or Vaccine Mitigation.Zhihua Bai,
Ying Cao, Wenjun Liu, Jing Li,
10.3390/v13061115PubMedReview2021-06-09Identification of FDA approved drugs
against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like
protease (3CLpro), drug repurposing approachZahra Molavi, Sara Razi, Seyed Amir
Mirmotalebisohi, Amirjafar Adibi, Marzieh Sameni, Farshid Karami, Vahid Niazi,
Zahra Niknam, Morteza Aliashrafi, Mohammad Taheri, Soudeh Ghafouri-Fard, Shabnam
Jeibouei, Soodeh Mahdian, Hakimeh Zali, Mohammad Mehdi Ranjbar, Mohsen
Yazdani,10.1016/j.biopha.2021.111544PMCReview2021-07-05Drug repurposing approach
to fight COVID-19Thakur Uttam Singh, Subhashree Parida, Madhu Cholenahalli
Lingaraju, Manickam Kesavan, Dinesh Kumar, Raj Kumar Singh
10.1007/s43440-020-00155-6PMCReview2021-06-21Rapamycin as a potential repurpose
drug candidate for the treatment of COVID-19Amjad Husain, Siddappa
N.Byrareddy10.1016/j.cbi.2020.109282PMCReview2021-06-21Comprehensive analysis of
drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19
therapies (Review)GeoMihai Nitulescu, Horia Paunescu, Sterghios A. Moschos,
Dimitrios Petrakis, Georgiana Nitulescu, George Nicolae Daniel Ion, Demetrios A.
Spandidos, Taxiarchis Konstantinos Nikolouzakis, Nikolaos Drakoulis, Aristidis
Tsatsakis10.3892/ijmm.2020.4608PMCReview2021-06-21Literature-based review of the
drugs used for the treatment of COVID-19Meda Venkatasubbaiah, P.Dwarakanadha
Reddy, Suggala V.Satyanarayana10.1016/j.cmrp.2020.05.013PMCReview2021-06-21Quest
for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action,
Clinical Development, Synthesis at Scale, and Outlook for Supply Chris De Savi,
David L. Hughes, Lisbet Kvaerno10.1021/acs.oprd.0c00233PMCReview2021-06-21

Showing 1 to 50 of 809 entries
 * Previous
 * 1
 * 2
 * 3
 * 4
 * 5
 * …
 * 17
 * Next

Show 102550100 entries
Search:

TitleStatusPhasesStart DatePrim. Comp. DateComp. DateFirst Post. Date
TitleStatusPhasesStart DatePrim. Comp. DateComp. DateFirst Post. Date
Zilucoplan® in Improving Oxygenation and Short- and Long-term Outcome of
COVID-19 Patients With Acute Hypoxic Respiratory FailureCompletedPhase
22020-05-212020-12-282021-04-082020-05-10Yinhu Qingwen Granula for the Treatment
of Severe CoVID-19Not yet recruitingPhase 2, Phase
32020-03-192021-03-292021-06-292020-03-16Yinhu Qingwen Decoction for the
Treatment of Mild / Common CoVID-19Active, not recruitingPhase 2, Phase
32020-02-262020-12-312020-12-312020-02-19Xiyanping Injection for the Treatment
of New Coronavirus Infected PneumoniaNot yet recruitingNot
Applicable2020-02-132020-05-132021-12-132020-02-18Worldwide Trends on COVID-19
Research After the Declaration of COVID-19 PandemicNot yet
recruiting2020-07-242020-08-142020-09-192020-07-06Will Hydroxychloroquine Impede
or Prevent COVID-19RecruitingPhase
32020-04-062020-06-292021-04-292020-04-09Vitamin C Infusion for the Treatment of
Severe 2019-nCoV Infected PneumoniaRecruitingPhase
22020-02-132020-09-292020-09-292020-02-10Virgin Coconut Oil as Adjunctive
Therapy for Hospitalized COVID-19 PatientsRecruitingPhase
22020-10-212021-06-292021-06-292021-04-18Viable Human SARS-CoV-2 Specific T Cell
Transfer in Patients at Risk for Severe COVID-19RecruitingPhase
12021-12-072023-01-312023-01-312021-02-20VentaProst in Subjects With COVID-19
Requiring Mechanical VentilationCompletedPhase
22020-09-142021-06-282021-06-282020-06-29Various Combination of Protease
Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of
COVID-19 : A Randomized Control TrialNot yet recruitingPhase
32020-04-142020-10-302020-11-292020-03-10Valsartan for Prevention of Acute
Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2
(COVID-19) Infection DiseaseNot yet recruitingPhase
42020-03-312020-06-302021-07-312020-04-05Utilizing the Crosstalk Among
Aerosolized Phenformin , Methylene Blue, Photodynamic Therapy , Zinc and
Potassium for Treating Severe COVID-19 Infection and Its Inflammatory
ComplicationNot yet recruitingPhase 1, Phase
22021-08-312021-09-302021-10-312021-08-11Utility of Lactoferrin as an Adjunct
Therapeutic Agent for COVID-19Not yet recruitingPhase 2, Phase
32020-05-312020-08-312020-10-312020-06-08Utility of Lactoferrin as a Preventive
Agent for Healthcare Workers Exposed to COVID-19Not yet recruitingPhase 2, Phase
32020-06-302020-08-312020-10-312020-06-10Usefulness of DORNASE in COVID-19 on
HFNONot yet recruitingPhase 42021-11-302022-02-282022-05-312021-11-30Use of cSVF
Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19
InfectionEnrolling by invitationEarly Phase
12020-03-242021-10-312021-12-302020-03-29University of Utah COVID-19
Hydrochloroquine TrialNot yet recruitingPhase
22020-04-132022-03-312023-03-312020-04-09Umifenovir in Hospitalized COVID-19
PatientsEnrolling by invitationPhase
42020-04-142020-04-212020-04-232020-04-16Ultramicronized Palmitoylethanolamide
(PEA) Treatment in Hospitalized Participants With COVID-19RecruitingPhase
22020-12-132021-08-132021-12-042020-11-05Ulinastatin for the Treatment of
COVID-19 in Hospitalized PatientsNot yet recruitingPhase 1, Phase
22022-01-312022-07-312022-07-312020-05-18TXA127 for the Treatment of Severe
COVID-19CompletedPhase 22021-02-092021-06-092021-06-092020-05-25TXA and Corona
Virus 2019 (COVID19) in OutpatientsNot yet recruitingPhase
22020-04-142020-10-142020-10-292020-04-07Trial to Study the Adjuvant Benefits of
Quercetin Phytosome in Patients With COVID-19CompletedPhase
32020-09-282021-03-272021-04-142020-10-07Trial to Promote Recovery From COVID-19
With Endocrine TherapyWithdrawnPhase
22021-03-312021-12-312021-12-312020-05-04Trial to Evaluate the Efficacy and
Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19
and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at
Increased Risk of SARS-CoV-2 InfectionActive, not recruitingPhase
32020-05-122021-03-282021-03-282020-04-23Trial to Evaluate the Efficacy and
Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other
Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities
(LTCF)Active, not recruitingPhase 32020-05-112021-06-292021-06-292020-04-12Trial
to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects
at High Risk of Severe IllnessNot yet recruitingPhase
32021-12-312022-03-312022-04-302021-12-13Trial to Evaluate Nitazoxanide for
Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe IllnessNot yet
recruitingPhase 32021-12-312022-02-282022-03-312021-12-13Trial to Evaluate
Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate
COVID-19CompletedPhase 32020-08-122021-02-072021-02-072020-07-23Trial of
Treatments for COVID-19 in Hospitalized AdultsRecruitingPhase
32020-03-212023-02-282023-02-282020-03-19Trial of Tocilizumab for Treatment of
Severe COVID-19: ARCHITECTSRecruitingPhase
32020-06-112021-12-302021-12-302020-06-01Trial of Imatinib for Hospitalized
Adults With COVID-19RecruitingPhase
32020-06-012022-05-312023-05-312020-05-18Trial of Early Therapies During
Non-hospitalized Outpatient Window for COVID-19Active, not recruitingPhase
22020-05-312022-03-312022-05-312020-05-03Trial Evaluating Efficacy and Safety of
Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the
Corimmuno-19 Cohort.Not yet recruitingPhase
22020-04-142020-07-302020-09-292020-04-12Trial Evaluating Efficacy and Safety of
Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in
the Corimmuno-19 CohortNot yet recruitingPhase
22020-04-142020-09-292020-11-292020-04-13Trial Evaluating Efficacy and Safety of
Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19
CohortNot yet recruitingPhase
22020-04-192020-07-302020-09-292020-04-13Treatments for COVID-19: Canadian Arm
of the SOLIDARITY TrialRecruitingPhase
22020-03-172022-03-172022-05-172020-03-31Treatment With Investigational
Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With
COVID-19RecruitingPhase 22020-04-272021-04-272025-04-272020-06-15Treatment of
SARS Caused by COVID-19 With RuxolitinibNot yet recruitingPhase 1, Phase
22020-03-312020-05-312020-05-312020-04-02Treatment of Pulmonary Fibrosis Due to
2019-nCoV Pneumonia With Fuzheng HuayuRecruitingPhase
22020-02-142022-11-302022-11-302020-02-20Treatment of Moderate to Severe
Coronavirus Disease (COVID-19) in Hospitalized PatientsRecruitingPhase
22020-04-162022-01-312022-02-282020-03-25Treatment of COVID-19 Patients With
Anti-interleukin DrugsCompletedPhase
32020-04-022020-12-172021-04-112020-03-31Treatment of COVID-19 Cases and
Chemoprophylaxis of Contacts as PreventionCompletedPhase
32020-03-172020-06-142020-06-142020-03-10Treatment of Acute Severe 2019-nCoV
Pneumonia With Immunoglobulin From Cured PatientsNot yet recruitingNot
Applicable2020-03-162020-04-292020-05-302020-02-10Treatment in Patients With
Suspected or Confirmed COVID-19 With Early Moderate or Severe DiseaseActive, not
recruitingPhase 32020-04-122021-04-092021-12-092020-04-13Treatment and
Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV
InfectionRecruitingNot
Applicable2020-01-212021-01-212021-01-212020-02-04Treating COVID-19 With
Hydroxychloroquine (TEACH)TerminatedPhase
22020-04-142021-03-312021-03-312020-04-29Transplantation of Deceased Donors With
COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab
Antibody CocktailNot yet recruitingPhase
12021-12-312023-12-312024-12-312021-12-14Tranexamic Acid (TXA) and Corona Virus
2019 (COVID19) in InpatientsNot yet recruitingPhase
22020-04-142020-10-142020-12-142020-04-07

Showing 1 to 50 of 641 entries
 * Previous
 * 1
 * 2
 * 3
 * 4
 * 5
 * …
 * 13
 * Next




CORDITE (CORona Drug InTEractions database) collects and aggregates data from
PubMed, MedRxiv, BioRxiv, ChemRxiv and PMC for SARS-CoV-2. Its main focus is set
on drug interactions either addressing viral proteins or human proteins that
could be used to treat COVID. It collects and provides up-to-date information on
computational predictions, in vitro, as well as in vivo study data.

The information provided is for research only and we cannot guarantee the
correctness of the data.

Please contact dominik.heider@uni-muenster.de for further information.

PROGRAMMABLE ACCESS

There is an open API for access programmatically to the database. The API will
print a JSON output:


 * Interactions
   
   https://cordite-api.uni-muenster.de/api.php?action=list&table=interaction

 * Targets
   
   https://cordite-api.uni-muenster.de/api.php?action=list&table=target

 * Drugs
   
   https://cordite-api.uni-muenster.de/api.php?action=list&table=drug

 * Publications
   
   https://cordite-api.uni-muenster.de/api.php?action=list&table=publication

 * Clinical trials
   
   https://cordite-api.uni-muenster.de/api.php?action=list&table=clinical_trial